Literature DB >> 29520705

Targeting BCL-2 in Hematologic Malignancies.

Nadia Khan1, Brad Kahl2.   

Abstract

Resistance to apoptosis is one of the hallmarks of cancer and members of the B-cell lymphoma 2 (BCL-2) family of proteins are central regulators of apoptosis. Many cancers become resistant to chemotherapy and apoptosis by up-regulating BCL-2 and other family members, making these proteins attractive targets for cancer therapy. Venetoclax is an orally administered, small-molecule apoptosis stimulant that targets BCL-2 proteins by acting as a BCL-2 homology domain 3 (BH3) mimetic. The drug is approved in the USA and EU as a monotherapy for the for the treatment of certain patients with chronic lymphocytic leukemia (CLL) and is in phase III clinical development for multiple myeloma (MM), and in phase II or I/II clinical trials for acute myeloid leukemia, and several B-cell malignancies, including diffuse large B-cell lymphoma, Waldenstrom's macroglobulinaemia, follicular lymphoma, and mantle-cell lymphoma.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29520705     DOI： 10.1007/s11523-018-0560-7

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


  30 in total

1.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Authors:  Victoria Del Gaizo Moore; Jennifer R Brown; Michael Certo; Tara M Love; Carl D Novina; Anthony Letai
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.

Authors:  Paula Hauck; Bo H Chao; Julie Litz; Geoffrey W Krystal
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

3.  Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Authors:  Kirsten Fischer; Othman Al-Sawaf; Anna-Maria Fink; Mark Dixon; Jasmin Bahlo; Simon Warburton; Thomas J Kipps; Robert Weinkove; Sue Robinson; Till Seiler; Stephen Opat; Carolyn Owen; Javier López; Kathryn Humphrey; Rod Humerickhouse; Eugen Tausch; Lukas Frenzel; Barbara Eichhorst; Clemens-M Wendtner; Stephan Stilgenbauer; Anton W Langerak; Jacque J M van Dongen; Sebastian Böttcher; Matthias Ritgen; Valentin Goede; Mehrdad Mobasher; Michael Hallek
Journal:  Blood       Date:  2017-03-21       Impact factor: 22.113

4.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Authors:  Matthew S Davids; Andrew W Roberts; John F Seymour; John M Pagel; Brad S Kahl; William G Wierda; Soham Puvvada; Thomas J Kipps; Mary Ann Anderson; Ahmed Hamed Salem; Martin Dunbar; Ming Zhu; Franklin Peale; Jeremy A Ross; Lori Gressick; Monali Desai; Su Young Kim; Maria Verdugo; Rod A Humerickhouse; Gary B Gordon; John F Gerecitano
Journal:  J Clin Oncol       Date:  2017-01-17       Impact factor: 44.544

Review 5.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

6.  Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Authors:  Stephan Stilgenbauer; Barbara Eichhorst; Johannes Schetelig; Steven Coutre; John F Seymour; Talha Munir; Soham D Puvvada; Clemens-Martin Wendtner; Andrew W Roberts; Wojciech Jurczak; Stephen P Mulligan; Sebastian Böttcher; Mehrdad Mobasher; Ming Zhu; Monali Desai; Brenda Chyla; Maria Verdugo; Sari Heitner Enschede; Elisa Cerri; Rod Humerickhouse; Gary Gordon; Michael Hallek; William G Wierda
Journal:  Lancet Oncol       Date:  2016-05-10       Impact factor: 41.316

7.  Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.

Authors:  Gabor Kovacs; Sandra Robrecht; Anna Maria Fink; Jasmin Bahlo; Paula Cramer; Julia von Tresckow; Christian Maurer; Petra Langerbeins; Günter Fingerle-Rowson; Matthias Ritgen; Michael Kneba; Hartmut Döhner; Stephan Stilgenbauer; Wolfram Klapper; Clemens-Martin Wendtner; Kirsten Fischer; Michael Hallek; Barbara Eichhorst; Sebastian Böttcher
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

8.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Authors:  Gerard Lozanski; Nyla A Heerema; Ian W Flinn; Lisa Smith; Jennifer Harbison; Jennifer Webb; Mollie Moran; Margaret Lucas; Thomas Lin; Marcy L Hackbarth; John H Proffitt; David Lucas; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

9.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

10.  Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

Authors:  Courtney D DiNardo; Caitlin R Rausch; Christopher Benton; Tapan Kadia; Nitin Jain; Naveen Pemmaraju; Naval Daver; Wendy Covert; Kayleigh R Marx; Morgan Mace; Elias Jabbour; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Kapil N Bhalla; Hagop Kantarjian; Marina Konopleva
Journal:  Am J Hematol       Date:  2017-12-23       Impact factor: 13.265
View more
  11 in total

Review 1.  Follicular Lymphoma: Past, Present, and Future.

Authors:  Melody R Becnel; Loretta J Nastoupil
Journal:  Curr Treat Options Oncol       Date:  2018-05-24

Review 2.  Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma.

Authors:  Alex Chan; Ahmet Dogan
Journal:  Surg Pathol Clin       Date:  2019-05-23

3.  PIK-75 overcomes venetoclax resistance via blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma.

Authors:  Shengjian Huang; Yang Liu; Zhihong Chen; Michael Wang; Vivian C Jiang
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

4.  HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib.

Authors:  Ziwen Lu; Zhixin Wang; Zhigang Tu; Hanqing Liu
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

Review 5.  Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Authors:  Lesley J Scott
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

6.  Effect of nucleolin on adriamycin resistance via the regulation of B-cell lymphoma 2 expression in Burkitt's lymphoma cells.

Authors:  Xuqiao Mei; Yanxin Chen; Donghui Gan; Yingyu Chen; Lingyan Wang; Yanqin Cao; Zhengjun Wu; Weijuan Liu; Chenxing Zhao; Minhui Lin; Ting Yang; Jianda Hu
Journal:  J Cell Physiol       Date:  2019-05-24       Impact factor: 6.384

Review 7.  Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance.

Authors:  Madeleine R Berendsen; Wendy B C Stevens; Michiel van den Brand; J Han van Krieken; Blanca Scheijen
Journal:  Cancers (Basel)       Date:  2020-11-28       Impact factor: 6.639

8.  FOXM1 Promotes Drug Resistance in Cervical Cancer Cells by Regulating ABCC5 Gene Transcription.

Authors:  Youxiang Hou; Zhanfei Dong; Wei Zhong; Linglong Yin; Xiong Li; Gulina Kuerban; He Huang
Journal:  Biomed Res Int       Date:  2022-01-31       Impact factor: 3.411

9.  Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance.

Authors:  Michela Colombo; Silvia Garavelli; Mara Mazzola; Natalia Platonova; Domenica Giannandrea; Raffaella Colella; Luana Apicella; Marialuigia Lancellotti; Elena Lesma; Silvia Ancona; Maria Teresa Palano; Marzia Barbieri; Elisa Taiana; Elisa Lazzari; Andrea Basile; Mauro Turrini; Anna Pistocchi; Antonino Neri; Raffaella Chiaramonte
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941

10.  Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas.

Authors:  Giulia Tadiotto Cicogna; Martina Ferranti; Annalisa Lazzarotto; Mauro Alaibac
Journal:  Front Oncol       Date:  2019-11-13       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.